Health Trials

Blasts 20-30 Percent of Bone Marrow Nucleated Cells

1

Review clinical trials related to Blasts 20-30 Percent of Bone Marrow Nucleated Cells. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

This phase II trial studies the side effects and how well azacitidine and enasidenib work in treating patients with IDH2-mutant myelodysplastic syndrome. Azacitidine and enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Participants needed: 63
Trial details
Phase: Phase 2Age: 12+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Aug 10, 2026Locations: 3
Eligibility criteria

Signed, informed consent must be obtained prior to any study specific procedures [+12]

Any prior or coexisting medical condition that in the investigator's judgment wi... [+9]

Read more